{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:23:58Z","timestamp":1768314238550,"version":"3.49.0"},"reference-count":35,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T00:00:00Z","timestamp":1550880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To develop a novel interactive budget impact model that assesses affordability of diabetes treatments in specific populations, and to test the model in a hypothetical scenario by estimating cost savings resulting from reduction in HbA<jats:sub>1c<\/jats:sub> from \u226569 mmol\/mol (8.5%) to a target of 53 mmol\/mol (7.0%) in adults with Type 1 diabetes in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A dynamic, interactive model was created using the projected incidence and progression over a 5\u2010year horizon of diabetes\u2010related complications (micro\u2010 and macrovascular disease, severe hypoglycaemia and diabetic ketoacidosis) for different HbA<jats:sub>1c<\/jats:sub> levels, with flexible input of population size, complications and therapy costs, HbA<jats:sub>1c<\/jats:sub> distribution and other variables. The model took a National Health Service and societal perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The model was developed, and in the proposed hypothetical situation, reductions in complications and expected costs evaluated. Achievement of target HbA<jats:sub>1c<\/jats:sub> in individuals with HbA<jats:sub>1c<\/jats:sub> \u226569 mmol\/mol (8.5%) would reduce expected chronic complications from 6.8 to 1.2 events per 100 person\u2010years, and diabetic ketoacidosis from 14.5 to 1.0 events per 100 person\u2010years. Potential cumulative direct cost savings achievable in the modelled population were estimated at \u00a3687 m over 5 years (\u00a35,585\/person), with total (direct and indirect) savings of \u00a31,034 m (\u00a38,400\/person).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Implementation of strategies aimed at achieving target glucose levels in people with Type 1 diabetes in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> has the potential to drive a significant reduction in complication costs. This estimate may provide insights into the potential for investment in achieving savings through improved diabetes care in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dme.13924","type":"journal-article","created":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T13:13:16Z","timestamp":1549113196000},"page":"988-994","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A modelling study of the budget impact of improved glycaemic control in adults with Type 1 diabetes in the <scp>UK<\/scp>"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7635-4735","authenticated-orcid":false,"given":"P.","family":"Choudhary","sequence":"first","affiliation":[{"name":"King's College London School of Life Course Sciences London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4982","authenticated-orcid":false,"given":"S.","family":"de Portu","sequence":"additional","affiliation":[{"name":"Medtronic International Trading Tolochenaz Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Delbaere","sequence":"additional","affiliation":[{"name":"Medtronic International Trading Tolochenaz Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lyon","sequence":"additional","affiliation":[{"name":"Medtronic UK Watford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4373-3269","authenticated-orcid":false,"given":"J. C.","family":"Pickup","sequence":"additional","affiliation":[{"name":"King's College London School of Life Course Sciences London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,2,23]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Diabetes prevalence 2017(November 2017). Available athttps:\/\/www.diabetes.org.uk\/professionals\/position-statements-reports\/statistics\/diabetes-prevalence-2017. Last accessed 21 March 2018."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03698.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2009.02.012"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1941"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187"},{"key":"e_1_2_9_7_1","first-page":"1307\u20131316","article-title":"Modern\u2010day clinical course of type 1 diabetes mellitus after 30 years\u2019 duration: the diabetes control and complications trial\/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983\u20102005)","volume":"169","author":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Research Group","year":"2009","journal-title":"Arch Intern Med"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12127"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0129"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12477"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_2_9_12_1","unstructured":"National Diabetes Audit \u2010 2015\u20102016: Report 1 Care Processes and Treatment Targets. NHS Digital 2017. Available athttps:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/national-diabetes-audit\/national-diabetes-audit-2015-2016-report-1-care-processes-and-treatment-targets. Last accessed 2 May 2018."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02413.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70323-6"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta19330"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12647"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005094"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0219-2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066454"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.02.06.dc05-1549"},{"key":"e_1_2_9_21_1","unstructured":"National Diabetes Audit \u20102012\u20102013 Report 2. NHS Digital 2015. Available athttps:\/\/digital.nhs.uk\/catalogue\/PUB16496. Last accessed 27 March 2018."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696990903336597"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/618039"},{"key":"e_1_2_9_24_1","unstructured":"Office for National Statistics.Average Weekly Earnings time series dataset (EMP). 2017. Available athttps:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/timeseries\/kab9\/emp. Last accessed 2 May 2018."},{"key":"e_1_2_9_25_1","unstructured":"Office for National Statistics.Consumer price inflation time series (MM23). 2017. Available athttps:\/\/www.ons.gov.uk\/economy\/inflationandpriceindices\/timeseries\/d7g7\/mm23. Last accessed 2 May 2018."},{"key":"e_1_2_9_26_1","unstructured":"National Institute for Health and Care Excellence.Type 1 diabetes in adults: diagnosis and management. NICE guideline 17 2016. Available athttps:\/\/www.nice.org.uk\/guidance\/ng17. Last accessed 23 October 2018."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13541"},{"key":"e_1_2_9_28_1","unstructured":"National Institute for Health and Clinical Excellence.Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. NICE technology appraisal guidance 151 2008. Available athttp:\/\/www.nice.org.uk\/nicemedia\/pdf\/ta151guidance.pdf. Last accessed 22 May 2018."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02486.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30297-6"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0615"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1431-6"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13062"},{"key":"e_1_2_9_34_1","first-page":"361\u2013376","article-title":"Implementation of treatment protocols in the Diabetes Control and Complications Trial","volume":"18","year":"1995","journal-title":"Diabetes Care"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12486"},{"issue":"1","key":"e_1_2_9_36_1","article-title":"Estimation of economic impact associated with CSII treatment in adult type 1 diabetes in the UK, according to NICE guidance","volume":"20","author":"Choudhary P","year":"2018","journal-title":"Diabetes Technol Ther"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.13924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dme.13924","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.13924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T16:45:27Z","timestamp":1694277927000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,23]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/dme.13924"],"URL":"https:\/\/doi.org\/10.1111\/dme.13924","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,23]]},"assertion":[{"value":"2019-01-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}